Cardiovascular Drugs in Older People

Total Page:16

File Type:pdf, Size:1020Kb

Load more

VOLUME 36 : NUMBER 6 : DECEMBER 2013 ARTICLE Cardiovascular drugs in older people Vasi Naganathan symptomatic postural hypotension in a frail older Associate professor SUMMARY person. In this situation, if the hypotension results in Centre for Education and falls, dizziness and impairment of everyday function Research on Ageing Cardiovascular drugs are the most frequently then avoiding postural hypotension should be the Sydney Medical School prescribed medicines for older people. priority even at the expense of less than ideal control University of Sydney However, it can be difficult to find a regimen of blood pressure. High blood pressure may have to Consultant geriatrician that does more good than harm, especially if be accepted as long as it is not causing symptoms. Concord Hospital the patient is frail. Sydney The consequences of a fractured hip as a result Prescribers should determine the goals of of a fall due to postural hypotension can be more treatment, understand the limitations of the devastating than the vascular events one was aiming Key words evidence and be vigilant for the adverse to prevent by lowering blood pressure. aged 80 and over, atrial fibrillation, heart failure, effects of cardiovascular drugs. Table 1 gives examples of how priorities may differ hypertension Regimens for common cardiovascular between a well older person and a frail older person diseases, such as hypertension, chronic heart for the treatment of specific cardiovascular diseases. Aust Prescr 2013;36:190–4 failure and chronic atrial fibrillation, need to Avoiding adverse effects is important in both groups, be tailored to the individual patient, taking but the risk of harm is greater in frail older people. In into account factors such as comorbidity and addition, mortality benefits are less likely to be seen in life expectancy. frail older people. Be aware of the limited evidence Introduction Older people are poorly represented in clinical trials,1 The prevalence of diseases such as hypertension, so there are limited data about the benefit and harm coronary heart disease, chronic heart failure and chronic atrial fibrillation increases with age, so cardiovascular drugs are the most frequently Box Guidelines for prescribing prescribed treatments for older people. These drugs cardiovascular drugs to older people are also responsible for a large proportion of the adverse drug reactions suffered by older people. 1. Take into account all the information obtained from a Important considerations when comprehensive assessment (e.g. postural hypotension, prescribing cognitive status, life expectancy) 2. Set goals of treatment – symptom control vs life There are some general principles to apply when prolongation prescribing cardiovascular drugs to older people 3. Understand and apply the evidence appropriately (Box). It is important to tailor a regimen for each 4. Avoid under-prescribing drugs that are likely to have individual patient. symptomatic and functional benefits (e.g. diuretics for Determine the goals of treatment chronic heart failure) 5. Be vigilant for adverse effects (see Table 2) Prescribers should ask themselves, ‘What outcome do I hope to achieve for this patient?’ The prescriber 6. Specifically look for drug–drug and drug–disease interactions should also consider what their patient hopes to 7. Discuss the potential benefits and harms with patient, achieve by following the treatment regimen. In general, family and carers cardiovascular drugs are helpful for symptom control, 8. Choose drugs wisely, start at a low dose and then prevention of cardiovascular events or life extension. increase the dose slowly In a healthy 80-year-old person all three goals may be 9. Try to avoid starting several drugs simultaneously applicable. In contrast, symptom control may be the 10. Conduct regular drug reviews only goal for an 80-year-old with severe dementia. 11. Stop drugs that are unlikely to be of benefit or are In frail older people with multiple comorbidities and likely to result in more harm than good functional limitations, it is important to prioritise the 12. Take a multidisciplinary approach to achieving optimal goals of treatment. These priorities should guide regimens (e.g. pharmacists can advise on simplifying prescribing. A common dilemma faced by clinicians the regimen and the best delivery system) is the combination of supine hypertension and 190 Full text free online at www.australianprescriber.com VOLUME 36 : NUMBER 6 : DECEMBER 2013 ARTICLE Table 1 Priorities of treatment for cardiovascular diseases in healthy and frail older people Disease Healthy older person Frail older person Hypertension Decrease risk of vascular events Avoid symptoms of hypertension and hypotension Decrease mortality Chronic heart failure Symptomatic relief Symptomatic relief Decrease admissions to hospital for decompensated Decrease admissions to hospital for decompensated acute heart failure acute heart failure Potential mortality benefit Avoid symptomatic hypotension and other adverse effects Anticoagulation for chronic Harm–benefit ratio usually favours anticoagulation Harm–benefit ratio may favour antiplatelet drug over atrial fibrillation anticoagulant Dyslipidaemia Decrease risk of vascular events Maintaining nutrition and treating malnutrition takes priority over dyslipidaemia of giving cardiovascular drugs to frail older patients. are therefore more likely to come to harm from Clinical guidelines for cardiovascular diseases rarely hypotension when prescribed cardiovascular drugs provide any details on how they should apply to older which lower blood pressure. This problem can be frail people with multiple comorbidities. Given these exacerbated by the blood pressure lowering effects of limitations, prescribers should choose a regimen drugs for Parkinson’s disease. which is appropriate for the individual patient and In addition, older people on many different drugs minimises the risk of harm. Prescribing purely on (polypharmacy) are at increased risk of adverse evidence from younger patients or disease-specific events, in part because of the increased likelihood of guidelines leads to polypharmacy, pill burden and drug–drug interactions. often harm. However, the lack of direct evidence To minimise the possibility of adverse drug reactions it should not be a reason to deny older people is a good idea to take a ‘start low, go slow’ approach treatments that have the potential to improve their when prescribing. If possible, start only one new drug quality of life. For example, treatment to minimise the at a time, at the lowest dose possible and increase the breathlessness of heart failure can have a big impact dose slowly while being vigilant for possible adverse on the everyday function and overall quality of life of effects. an older person. It is important to question and examine older people Be vigilant for adverse effects for possible adverse drug reactions. Often the Over the past 20 years there has been an increase symptoms can be non-specific such as falls, tiredness in hospital admissions due to adverse drug or confusion. An adverse drug reaction such as postural reactions particularly in people over 80 years old.2 hypotension can easily be missed if not looked for. It is Cardiovascular drugs are responsible for about important to be aware of the common problems that 20% of these reactions in this age group. Adverse could be the adverse effects of cardiovascular drugs drug reactions can occur even at recommended (see Table 2). Ask specifically about, and look for, these adult doses. As people become frailer and acquire adverse effects. Be particularly aware of drugs that new diseases a previously safe and tolerated have a narrow therapeutic window or a long half-life regimen may result in harm. Age-related changes such as digoxin and warfarin. in drug receptors, impairments in homeostatic The drug regimen should be easy to follow and, mechanisms and postural autonomic function are with the help of pharmacists, have packaging, labels just some of the reasons why older people are and dose administration aids that are easy to use. more sensitive to the hypotensive effects of many A general practitioner can order a home medicine cardiovascular drugs. review for people living in the community. A similar Older people are likely to have diseases that result scheme is funded to encourage a medication in disease–drug interactions. For example, people management review for patients in residential aged- with dementia may become more confused if they care facilities. are prescribed drugs that can cause confusion such as beta blockers. Frail older people with Parkinson’s Hypertension disease often have orthostatic hypotension due The Hypertension in the Very Elderly Trial (HYVET) to disease-related autonomic dysfunction. They found that treating hypertension (systolic blood Full text free online at www.australianprescriber.com 191 VOLUME 36 : NUMBER 6 : DECEMBER 2013 ARTICLE Cardiovascular drugs in older people pressure above 160 mmHg) in patients over 80 be made not to treat after weighing up the harms years old is beneficial in terms of all-cause mortality, and benefits. episodes of heart failure and deaths from strokes.3 The current National Heart Foundation hypertension However, it is important to be aware that participants guidelines4 recommend treating patients with were screened carefully for comorbidity including grade 2 and 3 hypertension (systolic >160 mmHg postural hypotension (systolic blood pressure less or diastolic >100 mmHg). For patients
Recommended publications
  • Ticagrelor Antidote) by Mathematical Modeling

    Ticagrelor Antidote) by Mathematical Modeling

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Chalmers Publication Library Citation: CPT Pharmacometrics Syst. Pharmacol. (2016) 5, 313–323; doi:10.1002/psp4.12089 VC 2016 ASCPT All rights reserved ORIGINAL ARTICLE Unraveling the Pharmacokinetic Interaction of Ticagrelor and MEDI2452 (Ticagrelor Antidote) by Mathematical Modeling J Almquist1,2,3, M Penney4, S Pehrsson3, A-S Sandinge3, A Janefeldt3, S Maqbool4, S Madalli5, J Goodman4, S Nylander3 and P Gennemark3* The investigational ticagrelor-neutralizing antibody fragment, MEDI2452, is developed to rapidly and specifically reverse the antiplatelet effects of ticagrelor. However, the dynamic interaction of ticagrelor, the ticagrelor active metabolite (TAM), and MEDI2452, makes pharmacokinetic (PK) analysis nontrivial and mathematical modeling becomes essential to unravel the complex behavior of this system. We propose a mechanistic PK model, including a special observation model for post-sampling equilibration, which is validated and refined using mouse in vivo data from four studies of combined ticagrelor-MEDI2452 treatment. Model predictions of free ticagrelor and TAM plasma concentrations are subsequently used to drive a pharmacodynamic (PD) model that successfully describes platelet aggregation data. Furthermore, the model indicates that MEDI2452-bound ticagrelor is primarily eliminated together with MEDI2452 in the kidneys, and not recycled to the plasma, thereby providing a possible scenario for the extrapolation to humans. We anticipate the modeling work to improve PK and PD understanding, experimental design, and translational confidence. CPT Pharmacometrics Syst. Pharmacol. (2016) 5, 313–323; doi:10.1002/psp4.12089; published online 16 June 2016. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE WHAT THIS STUDY ADDS TO OUR KNOWLEDGE TOPIC? þ A mathematical model describing the simultaneous þ Antiplatelet therapy for the prevention of athero- PKs of ticagrelor and MEDI2452 in the mouse is pre- thrombotic events in patients with acute coronary syn- sented.
  • Clopidogrel Compared with Other Antiplatelet Agents For

    Clopidogrel Compared with Other Antiplatelet Agents For

    Canadian Agency for Agence canadienne Drugs and Technologies des médicaments et des in Health technologies de la santé CADTH Technology Report Issue 131 Clopidogrel Compared with Other Antiplatelet November 2010 Agents for Secondary Prevention of Vascular Events in Adults Undergoing Percutaneous Coronary Intervention: Clinical and Cost-Effectiveness Analyses Supporting Informed Decisions Until April 2006, the Canadian Agency for Drugs and Technologies in Health (CADTH) was known as the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Publications can be requested from: CADTH 600-865 Carling Avenue Ottawa ON Canada K1S 5S8 Tel: 613-226-2553 Fax: 613-226-5392 Email: [email protected] or downloaded from CADTH’s website: http://www.cadth.ca Cite as: Chen SY, Russell E, Banerjee S, Hutton B, Brown A, Asakawa K, McGahan L, Clark M, Severn M, Cox J, Sharma M. Clopidogrel Compared with Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults Undergoing Percutaneous Coronary Intervention: Clinical and Cost-Effectiveness Analyses [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010 (Technology report; no. 131). [cited 2010-11-01]. Available from: http://www.cadth.ca/preview.php/en/publication/2708 Production of this report is made possible by financial contributions from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Prince Edward Island, Saskatchewan, and Yukon. The Canadian Agency for Drugs and Technologies in Health takes sole responsibility for the final form and content of this report. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government.
  • Multifactorial Background for a Low Biological Response to Antiplatelet Agents Used in Stroke Prevention

    Multifactorial Background for a Low Biological Response to Antiplatelet Agents Used in Stroke Prevention

    medicina Review Multifactorial Background for a Low Biological Response to Antiplatelet Agents Used in Stroke Prevention Adam Wi´sniewski Department of Neurology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru´n, Skłodowskiej 9 Street, 85-094 Bydgoszcz, Poland; [email protected]; Tel.: +48-79-0813513 Abstract: Effective platelet inhibition is the main goal of the antiplatelet therapy recommended as a standard treatment in the secondary prevention of non-embolic ischemic stroke. Acetylsalicylic acid (aspirin) and clopidogrel are commonly used for this purpose worldwide. A low biological response to antiplatelet agents is a phenomenon that significantly reduces the therapeutic and protective properties of the therapy. The mechanisms leading to high on-treatment platelet reactivity are still unclear and remain multifactorial. The aim of the current review is to establish the background of resistance to antiplatelet agents commonly used in the secondary prevention of ischemic stroke and to explain the possible mechanisms. The most important factors influencing the incidence of a low biological response were demonstrated. The similarities and the differences in resistance to both drugs are emphasized, which may facilitate the selection of the appropriate antiplatelet agent in relation to specific clinical conditions and comorbidities. Despite the lack of indications for the routine assessment of platelet reactivity in stroke subjects, this should be performed in selected patients from the high-risk group. Increasing the detectability of low antiaggregant responders, in light of its negative impact on the prognosis and clinical outcomes, can contribute to a more individualized approach and modification of the antiplatelet therapy to maximize the therapeutic effect in the secondary prevention of stroke.
  • What Are Anticoagulants and Antiplatelet Agents?

    What Are Anticoagulants and Antiplatelet Agents?

    ANSWERS Treatments + Tests by heart What are Blood clots are made up of red blood cells, platelets, fibrin, and white blood Anticoagulants cells (shown below). Anticoagulants and antiplatelets keep these parts from and Antiplatelet sticking together and forming a clot. Agents? Anticoagulants and antiplatelets are medicines that reduce blood clotting in an artery, vein or the heart. Doctors prescribe these to help prevent heart attacks and strokes caused by blood clots. Blood clots can block blood flow to your heart or your brain causing a heart attack or stroke. What should I know about anticoagulants? • Discuss your diet with your health care providers. Foods rich in Vitamin K can reduce the effectiveness of Anticoagulants (sometimes known as “blood thinners”) are warfarin. Vitamin K is in leafy, green vegetables, fish, medicines that delay the clotting of blood. Examples are liver, lentils, soybeans and some vegetable oils. heparin, warfarin, dabigitran, apixaban, rivoraxaban and edoxaban. • Tell your family that you take anticoagulant medicine. Anticoagulants make it harder for blood clots to form in your • Always carry your emergency medical ID card. heart, veins and arteries. They also can keep existing clots from growing larger. It’s important to follow these tips while on anticoagulants: Could anticoagulants cause problems? • Take your medications exactly as prescribed. If you do as your doctor tells you, there probably won’t be problems. But you must tell them right away if: • If you take warfarin, have regular blood tests so your health care provider can tell how the medicine is working. • You think you’re pregnant or you’re planning to get pregnant.
  • Medication Safety in Nursing Homes Change Package

    Medication Safety in Nursing Homes Change Package

    Medication Safety in Nursing Homes CHANGE PACKAGE Version 1 | June 2020 WWW.TMFNETWORKS.ORG TABLE OF CONTENTS Acronyms . 3 Introduction . 4 The Quality Improvement Process Using PDSA . 5 References . 23 Change Package Pain Management and Opioid Use 7 > Use evidence-based approaches to manage and treat acute and chronic pain . 7 > Educate residents, resident representatives, medical and clinical staff on safe use of opioids and alternative pain management strategies . 8 > Improve communication . 9 > Improve staff understanding of regulatory guidelines . .9 . Anticoagulant Medications 10 > Reduce number of ADEs Related to Anticoagulant Medications . 11 > Provide reference tools for providers . 11. > Improve communication . 12 > Provide resident education on anticoagulation therapy . .12 . > Increase staff understanding of regulatory guidelines . 13. Antipsychotic Medications 14 > Implement safe use of antipsychotic drugs in the long- and short-stay nursing home resident . 14 > Implement safe use of antipsychotic medications for those with dementia diagnosis . 15 > Improve communication . 15 > Increase staff understanding of regulatory guidelines . 16. Antimuscarinic Medications 17 > Reduce number of residents with a fall related to antimuscarinic medication . 17 > Improve communication . 18 > Increase staff understanding of regulatory guidelines . 18. Diabetes Medications 19 > Eliminate sliding-scale insulin . 20 . > Safe diabetes and medication management . 20 . > Improve communication . 21 > Reduce and prevent incidence of hypoglycemic events . 21 > Increase staff understanding of regulatory guidelines . 22. This material was developed by TMF Health Quality Institute, the Medicare Quality Innovation Network-Quality Improvement Organization, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. This content does not necessarily reflect CMS policy.
  • Acute Coronary Syndrome

    Acute Coronary Syndrome

    Abstracts Heart: first published as 10.1136/heartjnl-2011-300867.420 on 12 October 2011. Downloaded from Acute coronary syndrome http://heart.bmj.com/ [gw22-e0217] INFLUENCE OF RANITIDINE ON GASTROINTESTINAL HAEMORRHAGE AND THROMBOSIS INDUCED BY DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION Zhangqiang Chen, Lang Hong, Hong Wang, Qiulin Yao, Heng Li Lai, Linxiang Lu Jiangxi Provincial People´s Hospital, Jiangxi, China on October 1, 2021 by guest. Protected copyright. 10.1136/heartjnl-2011-300867.420 Background Percutaneous coronary intervention (PCI) is an effective treatment. method of coronary heart disease, particularly acute coronary syndrome. A large number of evidence-based medicine has shown that patients with coro- nary heart disease after PCI obtain clinical signifi cant benefi t in conjunction with clopidogrel and aspirin therapy, while the most common side effects of antiplatelet drugs is of gastric injury, that can lead to gastric bleeding, Thus, the American Heart Association/American Gastroenterological Association/ American Heart Association guidelines proposed the patients for the acceptance of dual antiplatelet therapy were treated with proton pump inhibitor (PPI) to reduce gastrointestinal complications such as ulcers and bleeding risk in 2008. But recently, the observation of basic and clinical research suggests that proton pump inhibitor (PPI) can reduce clopidogrel inhibi- tory effect on platelet aggregation, increasing major adverse cardiac events (MACE). H2 receptor antagonist ranitidine do not pass cytochrome P450 metabolism, would such gastric mucosa protective agents affect the clopidogrel and aspirin Heart October 2011 Vol 97 Suppl 3 A143 Heartnjl.indd Sec1:143 10/4/2011 10:07:32 PM Abstracts Heart: first published as 10.1136/heartjnl-2011-300867.420 on 12 October 2011.
  • Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

    Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

    pharmaceuticals Review Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues Milo Gatti 1,2,† , Eleonora Turrini 3,† , Emanuel Raschi 1,* , Piero Sestili 4 and Carmela Fimognari 3,* 1 Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum—Università di Bologna, Via Irnerio 48, 40126 Bologna, Italy; [email protected] 2 SSD Clinical Pharmacology, IRCCS Azienda Ospedaliero Universitaria Sant’Orsola, 40126 Bologna, Italy 3 Department for Life Quality Studies, Alma Mater Studiorum—Università di Bologna, C.so D’Augusto 237, 47921 Rimini, Italy; [email protected] 4 Department of Biomolecular Sciences (DISB), Università degli Studi di Urbino Carlo Bo, Via I Maggetti 26, 61029 Urbino, Italy; [email protected] * Correspondence: [email protected] (E.R.); carmela.fi[email protected] (C.F.) † These Authors contributed equally to this article. Abstract: We are witnessing a paradigm shift in drug development and clinical practice to fight the novel coronavirus disease (COVID-19), and a number of clinical trials have been or are being testing various pharmacological approaches to counteract viral load and its complications such as cytokine storm. However, data on the effectiveness of antiviral and immune therapies are still inconclusive and inconsistent. As compared to other candidate drugs to treat COVID-19, Janus Kinase (JAK) inhibitors, including baricitinib and ruxolitinib, possess key pharmacological features for a potentially successful Citation:
  • Reduction in the Incidence of Myocardial Infarction in Patients with Rheumatoid Arthritis Who Respond to Anti–Tumor Necrosis Factor ␣ Therapy

    Reduction in the Incidence of Myocardial Infarction in Patients with Rheumatoid Arthritis Who Respond to Anti–Tumor Necrosis Factor ␣ Therapy

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE ARTHRITIS & RHEUMATISM provided by PubMed Central Vol. 56, No. 9, September 2007, pp 2905–2912 DOI 10.1002/art.22809 © 2007, American College of Rheumatology Reduction in the Incidence of Myocardial Infarction in Patients With Rheumatoid Arthritis Who Respond to Anti–Tumor Necrosis Factor ␣ Therapy Results From the British Society for Rheumatology Biologics Register W. G. Dixon, K. D. Watson, M. Lunt, K. L. Hyrich, British Society for Rheumatology Biologics Register Control Centre Consortium, A. J. Silman, and D. P. M. Symmons, on behalf of the British Society for Rheumatology Biologics Register Objective. Rheumatoid arthritis (RA) is associ- rate of 4.8 events per 1,000 person-years and 5.9 events ated with an increased risk of coronary artery disease, per 1,000 person-years, respectively. After adjustment possibly acting via shared mechanisms of inflammation. for baseline risk factors, there was no reduction in the This study was undertaken to test the hypothesis that rate of MI in the anti-TNF␣ cohort compared with the the powerful antiinflammatory effect of anti–tumor DMARD cohort (incidence rate ratio 1.44 [95% confi- necrosis ␣ (anti-TNF␣) therapy might lead to a reduc- dence interval 0.56–3.67]). In an analysis of anti-TNF␣– tion in the incidence of myocardial infarction (MI) in treated patients who responded to the treatment within patients with RA. 6 months versus those who did not, MI rates were found Methods. Using data from the British Society for to be 3.5 events per 1,000 person-years in responders Rheumatology Biologics Register, a national prospective and 9.4 events per 1,000 person-years in nonresponders.
  • The Role of Corticosteroids in Primary Antiphospholipid Antibody Syndrome Presenting As Cerebral Venous Thrombosis in Young Females at Peripartum

    The Role of Corticosteroids in Primary Antiphospholipid Antibody Syndrome Presenting As Cerebral Venous Thrombosis in Young Females at Peripartum

    E. A. Ashok Kumar, P. Jijiya Bai. The role of corticosteroids in primary antiphospholipid antibody syndrome presenting as cerebral venous thrombosis in young females at peripartum. IAIM, 2016; 3(8): 97-110. Original Research Article The role of corticosteroids in primary antiphospholipid antibody syndrome presenting as cerebral venous thrombosis in young females at peripartum E. A. Ashok Kumar1*, P. Jijiya Bai2 1Professor, Department of Medicine, 2Professor, Department of Pathology, MNR Medical College and Hospital, Medak, Telangana, India *Corresponding author email: [email protected] International Archives of Integrated Medicine, Vol. 3, Issue 8, August, 2016. Copy right © 2016, IAIM, All Rights Reserved. Available online at http://iaimjournal.com/ ISSN: 2394-0026 (P) ISSN: 2394-0034 (O) Received on: 11-07-2016 Accepted on: 30-07-2016 Source of support: Nil Conflict of interest: None declared. How to cite this article: E. A. Ashok Kumar, P. Jijiya Bai. The role of corticosteroids in primary antiphospholipid antibody syndrome presenting as cerebral venous thrombosis in young females at peripartum. IAIM, 2016; 3(8): 97-110. Abstract The clinical study of cerebral venous thrombosis in antiphospholipid antibody syndrome in young females at peripartum was done to study the incidence of antiphospholipid antibodies in highly susceptible population groups most commonly at peripartum women. The presence of these antibodies points towards increased susceptibility to thrombosis and ischemic stroke apart from other manifestations in peripartum period. The age group most affected was between 20-25 years. Most of them were primipara. Many of the patients underwent Cesarean section before the presentation with the specific neurological complaint. None of the patients gave positive history for use of oral contraceptive pills.
  • Drug Class Review on Newer Antiplatelet Agents

    Drug Class Review on Newer Antiplatelet Agents

    Drug Class Review on Newer Antiplatelet Agents Final Report November 2005 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Janet H. Dailey, PharmD Peter Glassman, MBBS, MSc Marika Suttorp, MS Cony Rolón, BA Produced by Southern California Evidence-based Practice Center RAND 1700 Main Street, PO Box 2138 Santa Monica, CA 90407 Paul Shekelle, co-Director Sally Morton, co-Director Copyright © 2005 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Final Report Drug Effectiveness Review Project TABLE OF CONTENTS Introduction....................................................................................................................................4 Scope and Key Questions ..........................................................................................................7 Inclusion Criteria .......................................................................................................................7 Methods...........................................................................................................................................8
  • Psychoactive Properties of Culinary Spices

    Psychoactive Properties of Culinary Spices

    Taking the spice route: Psychoactive properties of culinary spices Intoxication and toxicity can mimic psychiatric symptoms any substances that are not typically thought of as “substances of abuse” possess—when adequate- Mly dosed—clinically meaningful psychoactive properties. In addition to the more familiar effects of alcohol, psychostimulants, opioids, Cannabis, and hallucinogens, you may encounter psychiatric phenomena resulting from abuse of more obscure substances, including culinary spices. The clinician treating a patient in an apparent intoxicated state who has a negative drug screen might ask that patient if he (she) abuses spices. This might be particularly relevant when treating patients thought to have limited access to il- licit substances or those with ready access to large amounts of spices, such as prisoners, young patients, and those working in the food service industry. Abuse of spices can be a problematic diagnosis © STOCKCREATIONS Patients may misuse culinary spices to achieve euphoria, or a James A. Bourgeois, OD, MD “natural high.” They may present with medical or psychiat- Clinical Professor Vice Chair, Clinical Affairs ric symptoms, including acute altered mental status, but the Department of Psychiatry/Langley Porter Psychiatric Institute psychoactive substances are not identified on routine toxicol- University of California San Francisco ogy studies. In addition, patients may not attribute their use San Francisco, California of spices for psychoactive effect to “drugs,” because these Usha Parthasarathi, MBBS materials are legal and readily available. This may lead to Assistant Clinical Professor misdiagnosis of a systemic medical disorder or a primary psy- Ana Hategan, MD chiatric illness to explain the patient’s symptoms and initiat- Associate Clinical Professor ing a psychotropic agent and other psychiatric services when • • • • a substance abuse program might be a more appropriate clini- Department of Psychiatry and Behavioural Neurosciences cal intervention.
  • Polypill Eligibility and Equivalent Intake in a Swiss Population-Based

    Polypill Eligibility and Equivalent Intake in a Swiss Population-Based

    www.nature.com/scientificreports OPEN Polypill eligibility and equivalent intake in a Swiss population‑based study Julien Castioni 1,2, Nazanin Abolhassani 1,2*, Peter Vollenweider 1, Gérard Waeber 1 & Pedro Marques‑Vidal 1 The polypill has been advocated for cardiovascular disease (CVD) management. The fraction of the population who could beneft from the polypill in Switzerland is unknown. Assess (1) the prevalence of subjects (a) eligible for the polypill and (b) already taking a polypill equivalent; and (2) the determinants of polypill intake in the frst (2009–2012) and second follow‑ups (2014–2017) of a population‑based prospective study conducted in Lausanne, Switzerland. The frst and the second follow‑ups included 5038 and 4596 participants aged 40–80 years, respectively. Polypill eligibility was defned as having a high CVD risk as assessed by an absolute CVD risk ≥ 5% with the SCORE equation for Switzerland and/or presenting with CVD. Four polypill equivalents were defned: statin + any antihypertensive with (A) or without (B) aspirin; statin + calcium channel blocker (CCB) (C); and statin + CCB + angiotensin‑converting enzyme inhibitor (D). The prevalence of polypill eligibility was 20.6% (95% CI 19.5–21.8) and 27.7% (26.5–29.1) in the frst and second follow‑up, respectively. However, only around one‑third of the eligible 29.5% (95% CI 26.7–32.3) and 30.4% (27.9–33.0) respectively, already took the polypill equivalents. All polypill equivalents were more prevalent among men, elderly and in presence of CVD. After multivariable adjustment, in both periods, male gender was associated with taking polypill equivalent A (OR: 1.93; 95% CI 1.45–2.55 and OR: 1.67; 95% CI 1.27–2.19, respectively) and polypill equivalent B (OR: 1.52; 95% CI 1.17–1.96 and OR: 1.41; 95% CI 1.07–1.85, respectively).